Pharmacotherapy for mild hypertension.

@article{Diao2012PharmacotherapyFM,
  title={Pharmacotherapy for mild hypertension.},
  author={Diana Y Diao and James M. Wright and David K Cundiff and François Gueyffier},
  journal={The Cochrane database of systematic reviews},
  year={2012},
  volume={8},
  pages={
          CD006742
        }
}
BACKGROUND People with no previous cardiovascular events or cardiovascular disease represent a primary prevention population. The benefits and harms of treating mild hypertension in primary prevention patients are not known at present. This review examines the existing randomised controlled trial (RCT) evidence. OBJECTIVES PRIMARY OBJECTIVE To quantify the effects of antihypertensive drug therapy on mortality and morbidity in adults with mild hypertension (systolic blood pressure (BP) 140… 
View on PubMed
scielo.br
102 Citations
Highly Influential Citations
2
Background Citations
25
Methods Citations
3
Results Citations
1

Figures from this paper

102 Citations

Citation Type

Citation Type

Pharmacotherapy for mild hypertension.
TLDR
Antihypertensive drugs used in the treatment of adults (primary prevention) with mild hypertension (systolic BP 140-159 mmHg and/or diastolic BP 90-99 mmHG) have not been shown to reduce mortality or morbidity in RCTs.
Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals.
TLDR
Moderate-quality evidence is provided to show that antihypertensive drugs do not reduce sudden death but do reduce both non-fatal myocardial infarction and fatal myocardia, suggesting that sudden cardiac death may not be caused primarily by acute myocardials.
Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis.
TLDR
Blood pressure-lowering therapy is likely to prevent stroke and death in patients with uncomplicated grade 1 hypertension, and withdrawal from treatment due to adverse effects was more common in the active groups.
Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews.
TLDR
This overview demonstrates high-quality evidence to support aspirin, BP-lowering therapy, and statins for primary ASCVD prevention and tobacco cessation drugs for smoking cessation.
Review: In patients with mild hypertension and no CV disease, BP-lowering drugs reduce stroke and mortality
  • M. Tanner
  • Medicine
    Annals of Internal Medicine
  • 2015
TLDR
In patients with mild hypertension and no diagnosed cardiovascular disease, blood pressurelowering drugs (vs placebo or less-intensive regimens) reduce stroke and mortality.
Cochrane review finds no proved benefit in drug treatment for patients with mild hypertension
  • J. Lenzer
  • Medicine
    BMJ : British Medical Journal
  • 2012
TLDR
A Cochrane review of studies conducted in the United Kingdom, Australia, and the United States has found that treating patients with stage 1 (mild) hypertension has no benefit, and patients should throw away their blood pressure pills and focus instead on far more effective as well as evidence based approaches.
Randomized Controlled Trials of Blood Pressure Lowering in Hypertension
TLDR
The results of these meta-analyses provide further support to current hypertension treatment guidelines by showing that BP lowering can significantly reduce major cardiovascular outcomes largely independent of the agents used, significant risk reduction is found at all hypertension grades (stages), and when systolic BP is lowered below a cut off of 140 mm Hg.
Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal.
TLDR
The results of these meta-analyses provide further support to current hypertension treatment guidelines by showing that BP lowering can significantly reduce major cardiovascular outcomes largely independent of the agents used, significant risk reduction is found at all hypertension grades (stages).
The Benefits of Detecting and Treating Mild Hypertension: What We Know, and What We Need to Learn
TLDR
The results are consistent with those of prior analyses in hypertension clinical outcome trials that showed that blood pressure reductions, even within this lower range, are associated with favorable cardiovascular outcomes and a recent guideline that recommended relaxing blood pressure goals in patients older than 60 years.
Waste and harm in the treatment of mild hypertension.
  • I. Heath
  • Medicine
    JAMA internal medicine
  • 2013
TLDR
The Cochrane Review concluded that antihypertensive drugs used in the treatment of otherwise healthy adults with mild hypertension have not been shown to reduce mortality or morbidity in randomized clinical trials.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 77 REFERENCES
Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis.
TLDR
Until the results of large long-term clinical trials evaluating the effects of calcium channel blockers and ACE inhibitors on cardiovascular disease incidence are completed, the available scientific evidence provides strong support for the current national guidelines, which recommend diuretics and beta-blockers as firstline agents and low-dose therapy for all antihypertensive agents.
Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug?
TLDR
Low-dose thiazide therapy can be prescribed as the first-line treatment of hypertension with confidence that the risk of death, coronary artery disease and stroke will be reduced, and was significantly better at reducing systolic blood pressure than the other drug classes.
Pharmacotherapy for hypertension in women of different races.
TLDR
Hypertension treatment lowers the relative and absolute risk of cardiovascular morbidity and mortality in women ages 55 years and older, and in African American women of all ages.
First-line drugs for hypertension.
TLDR
First-line low-dose thiazides reduce all morbidity and mortality outcomes and first-line ACE inhibitors and calcium channel blockers are inferior to first-liners beta-blockers.
Results of MRC (UK) trial of drug therapy for mild hypertension.
  • S. Peart
  • Medicine
    Clinical and investigative medicine. Medecine clinique et experimentale
  • 1987
TLDR
The main aim of the trial was to determine whether drug treatment of mild hypertension reduced the rates of stroke, of death due to hypertension, and of coronary events, in men and women aged 35-64 years.
New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit.
TLDR
The most constant treatment benefit concerned stroke, although the absolute reduction was very modest in younger patients with mild-to-moderate hypertension, and a trend towards greater absolute benefit under treatment was indicated.
Cardiovascular morbidity and mortality in mild hypertension: the Australian Trial.
  • A. Doyle
  • Medicine
    Journal of cardiovascular pharmacology
  • 1985
TLDR
The overall data showed that the treated group had a lower incidence of both death and of nonfatal cardiovascular events, and the effects of treatment seemed to be reduced in those with higher serum cholesterol levels.
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
TLDR
Low-dose diuretics are the most effective first-line treatment for preventing the occurrence of cardiovascular disease morbidity and mortality and future trials should use low-doseDiuretics as the standard for clinically useful comparisons.
The Australian Therapeutic Trial in Mild Hypertension.
In the Australian Therapeutic Trial in Mild Hypertension treated patients had significantly lower cardiovascular mortality and a significantly lower incidence of cerebrovascular complications than…
...
1
2
3
4
5
...